Key result
Growth hormone replacement therapy in patients with adult growth hormone deficiency significantly increased resting energy expenditure from 1278.0 kcal/day at baseline to 1511.1 kcal/day at 12 months.
Why the study?
Although growth hormone replacement in adult growth hormone deficiency improves body composition and metabolic rate, data regarding the relationship between body composition and energy expenditure are scarce.
Does recombinant human growth hormone replacement improve resting energy expenditure and body composition in patients with adult growth hormone deficiency?
Cohort (n=15)
Open-label
No
Does recombinant human growth hormone replacement improve resting energy expenditure and body composition in patients with adult growth hormone deficiency?
Answers are grounded in this paper and cite their sources.
Growth hormone replacement therapy in patients with adult growth hormone deficiency significantly improves resting energy expenditure and lean body mass over 12 months.
Numerous studies have shown that growth hormone (GH) replacement in adult GH deficiency (AGHD) improves the body composition and metabolic rate; however, data about the relationship between body composition and energy expenditure in these patients is scarce. Our study aimed to investigate the changes in resting energy expenditure (REE) and body composition after GH replacement in patients with AGHD. We enrolled 15 patients diagnosed with AGHD and evaluated the effect of GH replacement administered once daily for 12 months on REE, body composition measured by bioelectrical impedance analysis, and serological markers. GH replacement therapy significantly increased the serum insulin growth factor-1 levels after 4, 8, and 12 months. The REE and REE/basal energy expenditure (REE/BEE) ratio significantly increased from 1278.0 ± 490.0 kcal/day and 0.87 ± 0.23 at baseline to 1505.5 ± 449.2 kcal/day and 1.11 ± 0.21 at 4 months, 1,918.7 ± 631.2 kcal/day and 1.29 ± 0.27 at 8 months, and 1,511.1 ± 271.2 kcal/day, 1.14 ± 0.29 at 12 months (p < 0.005, p < 0.005; p < 0.01, p < 0.01; p < 0.01, p < 0.005, respectively). There was no change in the body weight, while the lean body mass increased significantly from 45.8 ± 9.5 kg at baseline to 46.9 ± 9.4 kg at 4 months and 47.5 ± 10.1 kg at 8 months (p < 0.005, p < 0.01, respectively). The fat mass also decreased at 12 months. Lipid metabolism improved after 4 and 8 months. GH replacement therapy in patients with AGHD significantly improved the REE and body composition.
No takes yet. Share an insight, caveat, or question.
Momozono et al. (2020) conducted a cohort in Adult growth hormone deficiency (n=15). Recombinant human growth hormone vs. Baseline was evaluated on Resting energy expenditure (REE) at 12 months (p=0.0091). Growth hormone replacement therapy in patients with adult growth hormone deficiency significantly increased resting energy expenditure from 1278.0 kcal/day at baseline to 1511.1 kcal/day at 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: